Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

Data of Blarcamesine confirm upstream SIGMAR1 activationPresented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease ...

On Friday, Anavex Life Sciences Corp (AVXL) stock saw a modest uptick, ending the day at $9.24 which represents a slight increase of $1.60 or 20.94% from the prior close of $7.64. The stock opened at ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company ...

China Universal Asset Management Co. Ltd. lifted its position in Anavex Life Sciences Corp. (NASDAQ:AVXL – Free Report) by 64.0% during the 3rd quarter, according to the company in its most recent ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.15% of ...

NEW YORK - Anavex Life Sciences Corp. (NASDAQ:AVXL), a biopharmaceutical company, has announced preliminary results from its Phase 2 study of ANAVEX®3-71, a treatment for schizophrenia.

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company ...

Missling, PhD, President and Chief Executive Officer of Anavex. “We believe the scalable and convenient features of blarcamesine could reduce crucial barriers within the currently complex ...